ABSTRACT

Background/Aim: Variceal bleeding is a life-threatening complication of portal hypertension with a high probability of recurrence. Treatment to prevent first bleeding or rebleeding is mandatory. The study has been aimed at investigating the effectiveness of endoscopic band ligation in preventing upper gastrointestinal bleeding in patients with portal hypertension and to establish the clinical outcome of patients. Patients and Methods: We analyzed in a multicenter trial, the efficacy and side effects of endoscopic band ligation for the primary and secondary prophylaxis of esophageal variceal bleeding. We assigned 603 patients with portal hypertension who were hospitalized to receive treatment with endoscopic ligation. Sessions of ligation were repeated every two to three weeks until the varices were eradicated. The primary end point was recurrent bleeding. Results: The median follow-up period was 32 months. A total of 126 patients had recurrent bleeding. All episodes were related to portal hypertension and 79 to recurrent variceal bleeding. There were major complications in 51 patients (30 had bleeding esophageal ulcers). Seventy-eight patients died, 26 deaths were related to variceal bleeding and 1 to bleeding esophageal ulcers. Conclusions: A great improvement in the prevention of variceal bleeding has emerged over the last years. However, further therapeutic options that combine higher efficacy, better tolerance and fewer side effects are needed.

Key Words: Endoscopic band ligation, esophageal varices, portal hypertension
Baseline evaluation and general management
A full clinical history, physical examination, electrocardiogram, chest radiograph, laboratory tests and ultrasonography were performed. Propranolol was initiated. The dose was increased stepwise, every two–three days, up to the maximum tolerated dose or up to 160 mg/day.

The first elective session was carried out within a mean of 12 days from the indication. Then EBL sessions were scheduled at an average of every 14 days until variceal eradication (disappearance of varices or being too small to be sucked in the banding device). EBL sessions were initially performed using single-band device with or without overtube; then with multiband ligation devices (SpeedBand, Boston Scientific, or Six Shooter Multi-Band ligator, Cook Medical) when they became commercially available; application of the bands was started at the gastro-esophageal junction and progressed upward in a helical way for approximately 5–8 cm. Procedures were performed under local sedation with xylocain.

Follow-up
After eradication, an endoscopic control was performed at one, three, six months and then yearly to monitor variceal recurrence, which was defined as the reappearance of varices, which could be ligated. Variceal recurrences were treated with repeat EBL. All patients underwent clinical reassessment every six months or more often if needed. Median follow-up was 32 months (range 2 – 212 months).

Untoward events considered to be related to treatment under study and requiring active therapy or prolonged hospitalization were recorded. Side effects were considered severe if the health or safety of the patient was endangered (i.e. pneumonia, sepsis, bacterial peritonitis or bleeding from esophageal ulcers). Minor symptoms or events, which were not considered worthy of treatment or investigation by the attending physician, were also recorded.

End points
The main endpoint of the study was bleeding from any source (first bleeding for primary prophylaxis and recurrent bleeding for secondary prophylaxis). Secondary endpoints were the number of banding sessions, the time to eradication (calculated from the first banding session), the incidence of variceal recurrence, variceal rebleeding, complications and mortality (overall and mortality related to bleeding).

All patients were instructed to come to hospital whenever they experienced melena or hematemesis. If bleeding was confirmed, an emergency endoscopy was performed. The diagnosis of variceal bleeding was done when varices were actively bleeding or had stigmata of recent bleeding and/or if fresh blood was observed in the stomach and varices were the only potential source of bleeding. Bleeding was considered to be EBL-related when endoscopy disclosed bleeding from an ulcer secondary to previous ligation. The rebleeding episode was treated primarily by means of vasoactive drugs (somatostatin) and endoscopic treatment, preferably with EBL.

RESULTS
Six hundred and three patients were included in the study. The indication of EBL was mainly a secondary prophylaxis (92%). The characteristics of the patients are shown in Table 1.

The cause of cirrhosis was hepatitis C (HCV) alone (34%), hepatitis B (HBV) alone (31%), cryptogenic (22.6%), combined HCV and HBV (1.28%), combined HBV and hepatitis D (0.37%), alcohol (3.8%), autoimmune hepatitis (3%), primary biliary cirrhosis (2.5%) and non-alcoholic fatty liver (1.45%).

Each varix was ligated at least once and up to seven bands were placed (mean four bands). Variceal eradication was achieved in 492 of the 603 patients (81.6%) with a mean of 3.5 EBL sessions (range 1–12 sessions) and after a median of nine weeks (range 2–32 weeks). The results of EBL according to the indication are resumed in Table 2. Concerning patient having active bleeding at endoscopy, the success rate of hemostasis achieved by ligation was 97%. Variceal eradication was not achieved in 111 patients (because of recurrent bleeding, death, lost to follow-up, or despite multiple EBL sessions). In 130 of the 492 patients achieving eradication

| Table 1: Clinical characteristics of the patients included in the study |
|-----------------------------|-----------|
| Characteristics             | 55 (10 – 95) |
| Age (years)                 | 55 (10 – 95) |
| Sex (male/female)           | 332 (55%) / 271 (45%) |
| Indication of band ligation | 49 (8%)  |
| Primary prophylaxis         | 544 (92%)  |
| Secondary prophylaxis       | 544 (92%)  |
| Etiology of portal hypertension |         |
| Cirrhosis                   | 91.5%     |
| Portal cavernoma            | 6.8%      |
| Nodular regenerative hyperplasia | 1%    |
| Congenital hepatic fibrosis | 0.7%      |
| Child Pugh class A/B/C (%)  | 22/56/22  |
| Esophageal varices           |           |
| Grade II                    | 186 (30.8%) |
| Grade III                   | 417 (69.2%) |
| Active bleeding at endoscopy (spurting or oozing) | 70 |
| Recent bleeding stigmata    | 50 |
| White nipple                | 28 |
| Clot over a varix           | 22 |
| Propranolol                 | 454 (75.3%) |
(26%), varices reappeared after a median of 35 weeks after eradication. Recurrent varices were eradicated by one to three sessions of EBL (mean two sessions and seven bands) in 110 cases (84.6%).

At the time of the index endoscopy, 343 patients had portal hypertensive gastropathie. At the last endoscopy performed during follow-up, 400 patients had portal hypertensive gastropathie, among them two had a worsening of the pre-existent lesions, with severe features. Concerning gastric varices, 35 patients had worsened pre-existent varices and 51 developed secondary varices after EBL.

Propranolol was prescribed in association with EBL in 454 patients as a secondary prophylaxis. The dosage was variable according to the patient (until the heart rate had fallen by 25%).

**Bleeding after EBL**

One hundred and twenty six patients bled during follow-up [Table 3]. In 30 patients bleeding was secondary to esophageal ulcers related to endoscopic treatment, in 15 to gastric varices and in 2 to portal hypertensive gastropathie. As a consequence, only 79 patients bled with confirmed esophageal variceal bleeding. The first variceal bleeding rate after EBL was 10.2% and the rebleeding rate was 13.3%. This variceal bleeding occurred less likely in patients on beta-blockers (15% vs. 18% in patients without beta-blockers) but the difference did not reach statistical significance.

**Survival**

Overall, 78 patients died (13%). Only 27 deaths were bleeding-related (esophageal varices = 14 cases, gastric varices = 12 cases and esophageal ulcers = 1 case); the other causes of death were spontaneous ascites infection (20 cases), hepatorenal syndrome (six cases), liver failure (nine cases), hepatocellular carcinoma (10 cases) and non-liver related cause (six cases).

**Adverse effects**

Overall, the number of patients with adverse events was 86. Major side effects occurred in 51 patients, which presented with esophageal ulcers. There was no case of aspiration pneumonia, bacterial peritonitis, empyema or sepsis.

Minor side effects were post-procedural chest pain (21 cases), fever (four cases), transient dysphagia (nine cases) and overtube’s migration (one case).

**DISCUSSION**

The indications for EBL of esophageal varices include control of acute variceal bleeding, primary prophylaxis to prevent the first episode of variceal bleeding in high-risk patients, and secondary prophylaxis to prevent rebleeding following an initial episode of acute variceal bleeding.[2,3]

Hemostatic treatment is essential in acute esophageal variceal bleeding, a medical emergency associated with relevant morbidity and mortality.[4] By combining both therapies, the local hemostatic effect induced by endoscopic treatment on the varices is added to the portal hypotensive effect achieved with drugs. This combination is the therapy of choice currently recommended for acute variceal. The use of variceal ligation instead of sclerotherapy as emergency endoscopic therapy for the treatment of acute variceal bleeding significantly improves the efficacy and safety.[4] EBL controlled bleeding in 97% of our patients whereas therapeutic success was 90% in the study of Villanueva et al.[1]

Non-selective beta-blockers are the recommended first line therapy for the primary prophylaxis of variceal hemorrhage in patients with varices at high risk for bleeding. Beta-blockers reduce the two-year incidence of first bleeding in these patients by 40%. [5] However, beta-blockers are not suitable for all patients: contraindications may be present in 5–20% of potential candidates, and 9–33% may develop side effects that lead to discontinuation of the treatment in 5–27% of cases.[5]

The optimal strategy to manage these patients is to treat with EBL, which achieve protection from variceal bleeding comparable to that of good responders to beta-blockers.[1,5,6] In this indication, the first bleeding rate was 10.2% comparable with that of other studies (8.9% in the study of Dell’Era et al.).[5]

| Table 2: Results of endoscopic band ligation according to the indication |
|-------------------------------------------------|-----------------|-----------------|
|                  | Primary prophylaxis | Secondary prophylaxis |
| Number of patients | 49 | 554 |
| Interval between sessions | 2 – 3 weeks | 2 – 3 weeks |
| Number of sessions to eradication (mean) | 3 | 3.5 |
| Number of bands (mean) | 12 | 14 |
| Time to eradication (weeks) | 8.5 | 9.5 |

| Table 3: Episodes of recurrent bleeding |
|----------------------------------------|-----------------|
| N | Patients with recurrent bleeding |
| Total number of episodes | 126 |
| Site of recurrent bleeding (N) | 126 |
| Esophageal varices | 79 |
| Esophageal ulcer | 30 |
| Portal hypertensive gastropathie | 2 |
| Gastric varices | 15 |

[1,5,6]
After an episode of acute esophageal variceal bleeding, patients are at high risk for recurrent bleeding and death. Thus, therapy to prevent recurrent bleeding is essential.\textsuperscript{[1,7,8]}

Endoscopic sclerotherapy is of proven benefit in such cases. However, it is associated with a rate of recurrent bleeding of up to 50\% and with local and systemic complications such as fever, pain, pulmonary infections, and esophageal ulceration, stricture, and perforation. Some of these complications may be fatal. Endoscopic variceal ligation is a purely mechanical method of obliterating varices that was introduced to preclude the undesirable effects of sclerotherapy. Several studies have shown that, as compared with sclerotherapy, variceal ligation is safer, requires fewer sessions to obliterate varices, significantly reduces the rate of recurrent bleeding, and improves the probability of survival.\textsuperscript{[1,2,8]}

Accordingly, endoscopic ligation is currently the preferred endoscopic treatment for preventing recurrent variceal bleeding. The efficacy of variceal ligation, as found in our study, is consistent with the higher ranges previously reported in randomized trials of this treatment. A relatively wide variation in rates of recurrent bleeding has been observed with ligation (10 to 50\%, 13.3\% in our study.\textsuperscript{[1,9,10]} This variation may be due, at least in part, to technical differences among studies, such as variations in the interval between sessions or in the number of bands placed during each session. Moreover, in multi-site band ligation-treated patients, eradication of varices seems to be achieved with fewer sessions of treatment than in those treated with conventional band ligation.\textsuperscript{[11]} Whether these or other technical differences can affect the outcome has not been adequately investigated. Other possible confounding factors, such as the time since the initial bleeding episode, alcohol use or non-use, and the treatment used to stop the bleeding, may also affect the results of treatment. Among different trials, there may be differences in the randomization process or in the characteristics of the population treated, such as the cause or the severity of hypertension, or in the definition of end points such as recurrent bleeding.\textsuperscript{[12-15]} Our study had few exclusion criteria; a high proportion of the patients had advanced liver disease. A combination of non-selective beta-blockers and EBL may be the best alternative.\textsuperscript{[1,16,17]}

It has also been suggested that, as with sclerotherapy, variceal ligation may worsen the severity of portal hypertensive gastropathie. We found that this condition rarely worsened or developed in patients treated with ligation.

CONCLUSION

In our population, endoscopic variceal ligation is a safe and effective technical approach. Moreover, the current study shows that using EBL as emergency endoscopic therapy added to vasoactive drugs is associated with a high rate of hemostasis. Variceal ligation is also effective and safe when beta-blockers are contraindicated or not tolerated for the prevention of first variceal bleeding. Concerning the secondary prophylaxis, combined therapy with propranolol seems to be more effective than endoscopic ligation for the prevention of recurrent bleeding.

REFERENCES

1. Garcia-Pagan JC, De Gottardi A, Bosch J. Review article: The modern management of portal hypertension – primary and secondary prophylaxis of variceal bleeding in cirrhotic patients. Aliment Pharmacol Ther 2008;28:178-86.
2. Baron TH, Wong Kee Song LM. Endoscopic variceal band ligation. Am J Gastroenterol 2009;104:1083-5.
3. Attwell AR, Chen YK. Endoscopic ligation in the treatment of variceal bleeding. Tech Gastrointest Endosc 2005;7:18-25.
4. Villanueva C, Piqueras M, Aracil C, Gomez C, Lopez-Balaguera JM, Gonzalez B, et al. A randomized controlled trial comparing ligation and sclerotherapy as emergency endoscopic treatment added to somatostatin in acute variceal bleeding. J Hepatol 2006;45:560-7.
5. Dell’Era A, Sotela JC, Fabris FM, Petazzi G, Reati R, Iannuzzi F, et al. Primary prophylaxis of variceal bleeding in cirrhotic patients: A cohort study. Dig Liv Dis 2008;40:936-43.
6. Lo GH, Chen WC, Chen MH, Lin CP, Lo CC, Hsu PL, et al. Endoscopic ligation vs. nadolol in the prevention of first variceal bleeding in patients with cirrhosis. Gastrointest Endosc 2004;59:333-8.
7. Garcia-Pagan JC, Villanueva C, Albillos A, Banares R, Morillas R, Abraldes JG, et al. Nadolol plus isosorbide mononitrate alone or associated with band ligation in the prevention of recurrent bleeding: A multicentre randomised controlled trial. Gut 2009;58:1144-50.
8. Villanueva C, Minana J, Ortiz J, Gallego A, Soriano G, Torras X, et al. Endoscopic ligation combined with combined treatment with nadolol and isosorbide mononitrate to prevent recurrent variceal bleeding. N Engl J Med 2001;345:647-55.
9. Silvanou S, Potenza I, Debernardi Venon W, Alessandria C, Bruno M, Musso A, et al. Endoscopic variceal ligation for prophylaxis of esophageal variceal bleeding: Technical aspects and outcome. Dig Liv Dis 2009;41:S:167.
10. Chandrasekhar V, Yepuri J, Sreenarasimanahait J. Clinical predictors for recurrence of esophageal varices after obliteration by Endoscopic Band ligation. Gastrointest Endosc 2007;65:148.
11. Nguyen KC, Nguyen TH. Efficacy of endoscopic multi-site band ligation in eradicating esophageal varices. Gastrointest Endosc 2009;69:222.
12. Spaander M, Murad SD, Van Buuren HR, Hansen BE, Kuipers EJ, Janssen H. Endoscopic treatment of esophagogastric variceal bleeding in patients with noncirrhotic extrahepatic portal vein thrombosis: A long-term follow-up study. Gastrointest Endosc 2008;67:821-7.
13. Zargar SA, Javid G, Khan BA, Shah OJ, Yatoo GN, Shah AH, et al. Endoscopic ligation vs. sclerotherapy in adults with extrahepatic portal venous obstruction: A prospective randomized study. Gastrointest Endosc 2005;61:58-66.
14. De Franchis R. Evolving consensus in portal hypertension report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 2005;43:167-76.
15. Garcia-Tsao G, Sanyal AJ, Grace ND. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis.
Variceal band ligation in the prevention of variceal bleeding

Hepatology 2007;46:922-38.

16. Gonzalez R, Zamora J, Gomez-Camarero J, Molinero LM, Banares R, Albillos A. Meta-analysis: Combination endoscopic and drug therapy to prevent variceal rebleeding in Cirrhosis. Ann Intern Med 2008;149:109-22.

17. Cheung J, Zeman M, Van Zanten VS, Tandon P. A systematic review and meta-analysis of secondary prophylaxis with band ligation, pharmacotherapy or combination therapy after esophageal variceal bleeding. Gastrointest Endosc 2009;67:315.

Source of Support: Nil, Conflict of Interest: None declared.